This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selleseth, D. W.
Right arrow Articles by Harvey, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selleseth, D. W.
Right arrow Articles by Harvey, R. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1468-1471, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1468-1471.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication

Dean W. Selleseth,* Christine L. Talarico, Teresa Miller, Michael W. Lutz, Karen K. Biron, and Robert J. Harvey

GlaxoSmithKline, Research Triangle Park, North Carolina 27709

Received 22 July 2002/ Returned for modification 21 October 2002/ Accepted 14 January 2003

Inhibition of human cytomegalovirus (HCMV) by 1263W94 was additive dosewise in combination with ganciclovir, acyclovir, and foscarnet. None of the commonly used anti-human immunodeficiency virus agents antagonized the inhibition of HCMV by 1263W94. The data were analyzed by a modified isobologram procedure that measures the strength and statistical significance of drug interactions.

* Corresponding author. Mailing address: Department of Virology, GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC 27709. Phone: (919) 483-9245. Fax: (919) 315-5243. E-mail: dean.w.selleseth{at}gsk.com.

Antimicrobial Agents and Chemotherapy, April 2003, p. 1468-1471, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1468-1471.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vigne, S., Duraffour, S., Andrei, G., Snoeck, R., Garin, D., Crance, J.-M. (2009). Inhibition of Vaccinia Virus Replication by Two Small Interfering RNAs Targeting B1R and G7L Genes and Their Synergistic Combination with Cidofovir. Antimicrob. Agents Chemother. 53: 2579-2588 [Abstract] [Full Text]  
  • Trofe, J., Pote, L., Wade, E., Blumberg, E., Bloom, R. D (2008). Maribavir: A Novel Antiviral Agent with Activity Against Cytomegalovirus. The Annals of Pharmacotherapy 42: 1447-1457 [Abstract] [Full Text]  
  • Garvey, E. P., Johns, B. A., Gartland, M. J., Foster, S. A., Miller, W. H., Ferris, R. G., Hazen, R. J., Underwood, M. R., Boros, E. E., Thompson, J. B., Weatherhead, J. G., Koble, C. S., Allen, S. H., Schaller, L. T., Sherrill, R. G., Yoshinaga, T., Kobayashi, M., Wakasa-Morimoto, C., Miki, S., Nakahara, K., Noshi, T., Sato, A., Fujiwara, T. (2008). The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral. Antimicrob. Agents Chemother. 52: 901-908 [Abstract] [Full Text]  
  • Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother. 51: 3147-3154 [Abstract] [Full Text]  
  • Chou, S., Marousek, G. I. (2006). Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.. Antimicrob. Agents Chemother. 50: 3470-3472 [Abstract] [Full Text]  
  • Hazen, R. J., Harvey, R. J., St. Clair, M. H., Ferris, R. G., Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R., Short, S. A., Romines, K. R., Chan, J. H., Boone, L. R. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for Resistance. Antimicrob. Agents Chemother. 49: 4465-4473 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»